Bespak and Cardinal Health in co-marketing agreement

Specialist UK drug delivery technology company Bespak has signed a co-marketing agreement with US-based Cardinal Health, a provider of products and services supporting the healthcare industry.

Under the agreement, Bespak will promote Cardinal Health's inhalation formulation development and analytical and clinical manufacturing services while Cardinal Health will leverage Bespak's drug delivery device technologies. The collaboration will provide customers of both companies with access to complementary products and services to help decrease time from drug development to marketing.

'The collaboration is a natural fit, both in terms of service offerings and geographic proximity, and will facilitate a seamless transition from product design and formulation to manufacturing and packaging of respiratory products,' said Sylvia Rossi-Montero, Bespak senior director of business development, North America.

'Customers are increasingly seeking specialised delivery systems, due in part to a recent FDA mandate requiring dosage counters on devices and for systemic delivery which requires more precise dosing,' added Danna Ross, vice president of inhalation at Cardinal Health. 'The Bespak collaboration is a natural step as Cardinal Health broadens the range of outsourcing services for pharmaceutical and biotech companies.'